OpenEvidence offers ‘ChatGPT for doctors’ and learns only from verified medical journals
Short summary
OpenEvidence is an AI search tool for doctors that indexes only peer-reviewed journals and clinical guidelines. Clinicians verify their credentials to access aggregated, real-time research from sources like JAMA and NEJM, cutting down on AI hallucinations. The free, ad-supported platform has just closed a $200 million Series C round at a $6 billion valuation.
- OpenEvidence raised $200M just three months after its $210M Series B, hitting a $6B valuation
- It's a credential-gated AI search tool for doctors that only pulls from peer-reviewed sources like JAMA, NEJM, PubMed, CDC and FDA to avoid hallucinations
- It's explicitly not for patients—designed to help doctors stay current on unfamiliar diseases, treatments, or new protocols
- The platform is free and ad-supported
Full summary
OpenEvidence launched in 2022 with a simple goal: give doctors instant access to peer-reviewed research. After raising $210 million in Series B, it secured another $200 million just three months later, pushing its valuation to $6 billion. Providers log in with their National Provider Identifier and a secondary proof—medical school records or state license—and then type questions as they would on Google. Within seconds, OpenEvidence’s AI search algorithms dig through full-text archives from partners like the JAMA Network, New England Journal of Medicine, PubMed, the CDC and the FDA. The system surfaces exact guidelines, papers and reviews, then wraps them in a conversational answer, all while linking back to original sources so clinicians can verify every citation.
Travis Zack, OpenEvidence’s chief medical officer, stresses that the tool isn’t for patients. It’s built to keep doctors in the loop on diseases or treatments they encounter less often, or when new protocols emerge. Sanjana Vig, an anesthesiologist and health-tech investor, uses it to stay current on cardiac updates. Plastic surgeon Antonio Forte relies on it to compare surgical options for complex patients. Unlike general-purpose LLMs that might hallucinate or pull from unvetted forums, OpenEvidence restricts its database to trusted journals. It updates new publications the moment they’re out, aiming to cut the time clinicians spend leafing through textbooks or disparate websites—and to shore up decisions with the latest verified evidence.